FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisition
Publishing timestamp: 2023-09-01 09:45:27
Summary
The Federal Trade Commission has reached a deal with Amgen to allow its $27.8 billion purchase of Horizon Therapeutics to proceed. However, Amgen is prohibited from "bundling" two of Horizon's drugs and must seek approval from the FTC for any products that treat the same diseases. The agreement resolves a lawsuit filed by the FTC and also involves the dismissal of federal suits by several attorneys general.
Sentiment: MIXED
Tickers: SGEN, META, PFE, AMGN, MSFT, HZNP,
Keywords: seagen inc, biotech and pharmaceuticals, federal trade commission, horizon therapeutics plc, amgen inc, health care industry, biotechnology, breaking news: business, pfizer inc, pharmaceuticals, microsoft corp, business news, business, meta platforms inc, products and services,
Source: https://www.cnbc.com/2023/09/01/ftc-allows-amgen-horizon-therapeutics-deal-to-move-forward.html